There has been a significant increase in cross-border investment (FDI) in the US life sciences industry, including both medtech and biopharmaceutical companies. Determining if life sciences companies, particularly those in the venture capital and start-up communities, have “critical technology” or “sensitive personal data” that would trigger CFIUS-filling can be a fact-intensive exercise because it involves determining if an export license would be required for the foreign investor(s) in...By: Morgan Lewis.